Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28267396 | 1.00 | SLC7A5 (0.65) | SLC7A5TAAR1SLC6A2HDAC8ESR1 | |
| SCHEMBL9523993 | 0.87 | SLC7A5 (0.62) | SLC7A5TAAR1SLC6A2HDAC8ESR1 | |
| SCHEMBL4453960 | 0.87 | SLC7A5 (0.67) | SLC7A5TAAR1SLC6A2HDAC8ESR1 | |
| SCHEMBL27680265 | 0.87 | SLC7A5 (0.67) | SLC7A5TAAR1SLC6A2HDAC8ESR1 | |
| SCHEMBL17738628 | 0.85 | SLC7A5 (0.65) | SLC7A5TAAR1SLC6A2HDAC8ESR1 | |
| SCHEMBL1253728 | 0.85 | SLC7A5 (0.65) | SLC7A5TAAR1SLC6A2HDAC8ESR1 | |
| SCHEMBL8012238 | 0.85 | SLC7A5 (0.65) | SLC7A5TAAR1SLC6A2HDAC8ESR1 | |
| SCHEMBL11456 | 0.85 | SLC7A5 (0.65) | SLC7A5TAAR1SLC6A2HDAC8ESR1 | |
| SCHEMBL18025358 | 0.85 | SLC7A5 (0.65) | SLC7A5TAAR1SLC6A2HDAC8ESR1 | |
| Tyrosine Methyl Ester SCHEMBL314923 | 0.84 | ESR1 (0.63) | SLC7A5TAAR1SLC6A2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216524-A1 | Chemoselective Rapid Azo-Coupling Reaction for Bioconjugation | TRUSTEES BOSTON COLLEGE (US) | 2024-07-04 | — | — | US | claimed |
| US-20180360984-A1 | Chemoselective Rapid Azo-Coupling Reaction for Bioconjugation | TRUSTEES OF BOSTON COLLEGE | 2018-12-20 | — | — | US | claimed |
| EP-2306192-B1 | Risk Markers For Cardiovascular Disease | CLEVELAND CLINIC FOUNDATION (US) | 2015-10-14 | — | — | EP | claimed |
| US-9005904-B2 | Risk markers for cardiovascular disease | THE CLEVELAND CLINIC FOUNDATION (US) | 2015-04-14 | — | — | US | claimed |
| US-20150037905-A1 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2015-02-05 | — | — | US | claimed |
| US-8722344-B2 | Risk markers for cardiovascular disease | THE CLEVELAND CLINIC FOUNDATION (US) | 2014-05-13 | — | — | US | claimed |
| CN-103458888-A | Nutritional compositions comprising branched chain fatty acids for improving intestinal barrier function | NESTEC SA | 2013-12-18 | — | — | CN | claimed |
| US-20130177551-A1 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | HAZEN STANLEY L (US) | 2013-07-11 | — | — | US | claimed |
| US-8338110-B2 | determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample; atherosclerosis | THE CLEVELAND CLINIC FOUNDATION (US) | 2012-12-25 | — | — | US | claimed |
| EP-1697746-B1 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | CLEVELAND CLINIC FOUNDATION (US) | 2012-02-22 | — | — | EP | claimed |
| EP-2306192-A2 | Risk Markers For Cardiovascular Disease | The Cleveland Clinic Foundation (US) | 2011-04-06 | — | — | EP | claimed |
| US-7781219-B2 | determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample; atherosclerosis | THE CLEVELAND CLINIC FOUNDATION (US) | 2010-08-24 | — | — | US | claimed |
| US-20100183607-A1 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2010-07-22 | — | — | US | claimed |
| EP-1697746-A4 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | CLEVELAND CLINIC FOUNDATION (US) | 2007-08-29 | — | — | EP | claimed |
| US-20070178554-A1 | Orthogonal Aminoacyl Synthetase-tRNA Pairs for Incorporating Unnatural Amino Acids Into Proteins | NEURION PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| EP-1697746-A2 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | The Cleveland Clinic Foundation (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2006039717-A2 | METHODS OF DETERMINING PRECISE HERG INTERACTIONS AND ALTERING COMPOUNDS BASED ON SAID INTERACTIONS | NEURION PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | claimed |
| US-20060014159-A1 | Methods of determining precise HERG interactions and designing compounds based on said interactions | NEURION PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-20050239136-A1 | Risk markers for cardiovacular disease | THE CLEVELAND CLINIC FOUNDATION | 2005-10-27 | — | — | US | claimed |
| WO-2005055810-A2 | RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2005-06-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014159-A1 | Methods of determining precise HERG interactions and designing compounds based on said interactions | KCNN4, KCNC1, HCN4 | SLC7A5 810/4885TAAR1 3479/4885SLC6A2 1280/4885 |
| US-20240216524-A1 | Chemoselective Rapid Azo-Coupling Reaction for Bioconjugation | PAICS, DNPEP, ABCG2 | SLC7A5 127/4885TAAR1 2476/4885SLC6A2 1927/4885 |
| US-20180360984-A1 | Chemoselective Rapid Azo-Coupling Reaction for Bioconjugation | PAICS, DNPEP, ABCG2 | SLC7A5 127/4885TAAR1 2476/4885SLC6A2 1927/4885 |
| US-20070178554-A1 | Orthogonal Aminoacyl Synthetase-tRNA Pairs for Incorporating Unnatural Amino Acids Into Proteins | AARS1, GARS1, TRMT1 | SLC7A5 171/4885TAAR1 3883/4885SLC6A2 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.